Skip to main navigation
Skip to search
Skip to main content
The Capital Region of Denmark's Research Portal Home
Dansk
English
Search content at The Capital Region of Denmark's Research Portal
Home
Hospitals/departments
Researchers
Research output
Activities
Prizes
Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study
A Briggs, H Glick, G Lozano-Ortega, M Spencer, P Calverley, P Jones, J Vestbo, NN NN
Department of Cardiology
Respiratory Unit
57
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Placebo
100%
TORCH
100%
Economic Analysis
100%
Quality-adjusted Life Years
83%
Salmeterol
66%
Fluticasone Propionate
66%
Medication Cost
33%
Cost-effectiveness
33%
EQ-5D
33%
Missing Data
16%
Multicenter Trial
16%
Monotherapy
16%
Treatment Efficacy
16%
Regression Model
16%
Western Europe
16%
Life Cost
16%
All-cause Hospitalization
16%
Survival Study
16%
Incremental Cost-effectiveness Ratio
16%
Missing Regions
16%
Outpatient Care
16%
Health Care Costs
16%
Medication Care
16%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Chronic Obstructive Lung Disease
100%
Fluticasone Propionate
50%
Salmeterol
50%
Monotherapy
16%
Fluticasone Propionate Plus Salmeterol
16%
Biochemistry, Genetics and Molecular Biology
Quality Adjusted Life Year
100%
Fluticasone Propionate
80%
Salmeterol
80%
Agricultural and Biological Sciences
Placebo
100%
Fluticasone Propionate
66%
Salmeterol
66%